Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Breast 1

Conditions

Prostatic Neoplasms 25Breast Neoplasms 22Salivary Gland Neoplasms 3Prostate Adenocarcinoma 2Neoplasm Metastasis 2Breast Neoplasms, Male 2Triple Negative Breast Neoplasms 1Stage I Prostate Adenocarcinoma AJCC v7 1Sexual Dysfunctions, Psychological 1Primary Dysautonomias 1Patient Compliance 1PSA Level Greater Than Two 1Kidney Diseases 1Hypertension 1Hormone Sensitive Prostate Cancer 1Hereditary Sensory and Autonomic Neuropathies 1HER2-positive Breast Cancer 1HER2 Negative Breast Cancer 1Castrate Sensitive Prostate Cancer 1Bulbo-Spinal Atrophy, X-Linked 1Anatomic Stage I Breast Cancer AJCC v8 1Advanced Breast Cancer 1

Interventions

Trastuzumab 14pertuzumab 10Docetaxel 7tucatinib 4pyrotinib 4Paclitaxel 4Capecitabine 4Carboplatin 2Ado-Trastuzumab Emtansine 2trastuzumab deruxtecan 1pegfilgrastim 1neratinib 1exemestane 1dalpiciclib 1atezolizumab 1Neoadjuvant Therapy 1Leuprolide 1Isovaleryl-CoA Dehydrogenase 1Injections 1Goserelin 1Genetic Testing 1Fulvestrant 1Fluorodeoxyglucose F18 1Blood Specimen Collection 1Anastrozole 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
HER2-positive Breast Cancer × Goserelin × 1 year × Clear all
NCT07179939 2025-09-18

Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study

Fudan University

Phase 2 Not yet recruiting
288 enrolled
Breast

HER2-positive Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡